Cargando…
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
BACKGROUND: A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. Thus, ribosome biogenesis might be an innovative source of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092774/ https://www.ncbi.nlm.nih.gov/pubmed/35545761 http://dx.doi.org/10.1186/s12885-022-09552-x |
_version_ | 1784705198702198784 |
---|---|
author | Nguyen Van Long, Flora Lardy-Cleaud, Audrey Carène, Dimitri Rossoni, Caroline Catez, Frédéric Rollet, Paul Pion, Nathalie Monchiet, Déborah Dolbeau, Agathe Martin, Marjorie Simioni, Valentin Bray, Susan Le Beherec, Doris Mosele, Fernanda Bouakka, Ibrahim Colombe-Vermorel, Amélie Odeyer, Laetitia Diot, Alexandra Jordan, Lee B. Thompson, Alastair M. Jamen, Françoise Dubois, Thierry Chabaud, Sylvie Michiels, Stefan Treilleux, Isabelle Bourdon, Jean-Christophe Pérol, David Puisieux, Alain André, Fabrice Diaz, Jean-Jacques Marcel, Virginie |
author_facet | Nguyen Van Long, Flora Lardy-Cleaud, Audrey Carène, Dimitri Rossoni, Caroline Catez, Frédéric Rollet, Paul Pion, Nathalie Monchiet, Déborah Dolbeau, Agathe Martin, Marjorie Simioni, Valentin Bray, Susan Le Beherec, Doris Mosele, Fernanda Bouakka, Ibrahim Colombe-Vermorel, Amélie Odeyer, Laetitia Diot, Alexandra Jordan, Lee B. Thompson, Alastair M. Jamen, Françoise Dubois, Thierry Chabaud, Sylvie Michiels, Stefan Treilleux, Isabelle Bourdon, Jean-Christophe Pérol, David Puisieux, Alain André, Fabrice Diaz, Jean-Jacques Marcel, Virginie |
author_sort | Nguyen Van Long, Flora |
collection | PubMed |
description | BACKGROUND: A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. Thus, ribosome biogenesis might be an innovative source of biomarkers that remains to be evaluated. METHODS: Here, fibrillarin (FBL) was used as a surrogate marker of ribosome biogenesis due to its essential role in the early steps of ribosome biogenesis and its association with poor prognosis in breast cancer when overexpressed. Using 3,275 non-metastatic primary breast tumors, we analysed FBL mRNA expression levels and protein nucleolar organisation. Usage of TCGA dataset allowed transcriptomic comparison between the different FBL expression levels-related breast tumours. RESULTS: We unexpectedly discovered that in addition to breast tumours expressing high level of FBL, about 10% of the breast tumors express low level of FBL. A correlation between low FBL mRNA level and lack of FBL detection at protein level using immunohistochemistry was observed. Interestingly, multivariate analyses revealed that these low FBL tumors displayed poor outcome compared to current clinical gold standards. Transcriptomic data revealed that FBL expression is proportionally associated with distinct amount of ribosomes, low FBL level being associated with low amount of ribosomes. Moreover, the molecular programs supported by low and high FBL expressing tumors were distinct. CONCLUSION: Altogether, we identified FBL as a powerful ribosome biogenesis-related independent marker of breast cancer outcome. Surprisingly we unveil a dual association of the ribosome biogenesis FBL factor with prognosis. These data suggest that hyper- but also hypo-activation of ribosome biogenesis are molecular traits of distinct tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09552-x. |
format | Online Article Text |
id | pubmed-9092774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90927742022-05-12 Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer Nguyen Van Long, Flora Lardy-Cleaud, Audrey Carène, Dimitri Rossoni, Caroline Catez, Frédéric Rollet, Paul Pion, Nathalie Monchiet, Déborah Dolbeau, Agathe Martin, Marjorie Simioni, Valentin Bray, Susan Le Beherec, Doris Mosele, Fernanda Bouakka, Ibrahim Colombe-Vermorel, Amélie Odeyer, Laetitia Diot, Alexandra Jordan, Lee B. Thompson, Alastair M. Jamen, Françoise Dubois, Thierry Chabaud, Sylvie Michiels, Stefan Treilleux, Isabelle Bourdon, Jean-Christophe Pérol, David Puisieux, Alain André, Fabrice Diaz, Jean-Jacques Marcel, Virginie BMC Cancer Research BACKGROUND: A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. Thus, ribosome biogenesis might be an innovative source of biomarkers that remains to be evaluated. METHODS: Here, fibrillarin (FBL) was used as a surrogate marker of ribosome biogenesis due to its essential role in the early steps of ribosome biogenesis and its association with poor prognosis in breast cancer when overexpressed. Using 3,275 non-metastatic primary breast tumors, we analysed FBL mRNA expression levels and protein nucleolar organisation. Usage of TCGA dataset allowed transcriptomic comparison between the different FBL expression levels-related breast tumours. RESULTS: We unexpectedly discovered that in addition to breast tumours expressing high level of FBL, about 10% of the breast tumors express low level of FBL. A correlation between low FBL mRNA level and lack of FBL detection at protein level using immunohistochemistry was observed. Interestingly, multivariate analyses revealed that these low FBL tumors displayed poor outcome compared to current clinical gold standards. Transcriptomic data revealed that FBL expression is proportionally associated with distinct amount of ribosomes, low FBL level being associated with low amount of ribosomes. Moreover, the molecular programs supported by low and high FBL expressing tumors were distinct. CONCLUSION: Altogether, we identified FBL as a powerful ribosome biogenesis-related independent marker of breast cancer outcome. Surprisingly we unveil a dual association of the ribosome biogenesis FBL factor with prognosis. These data suggest that hyper- but also hypo-activation of ribosome biogenesis are molecular traits of distinct tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09552-x. BioMed Central 2022-05-11 /pmc/articles/PMC9092774/ /pubmed/35545761 http://dx.doi.org/10.1186/s12885-022-09552-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Nguyen Van Long, Flora Lardy-Cleaud, Audrey Carène, Dimitri Rossoni, Caroline Catez, Frédéric Rollet, Paul Pion, Nathalie Monchiet, Déborah Dolbeau, Agathe Martin, Marjorie Simioni, Valentin Bray, Susan Le Beherec, Doris Mosele, Fernanda Bouakka, Ibrahim Colombe-Vermorel, Amélie Odeyer, Laetitia Diot, Alexandra Jordan, Lee B. Thompson, Alastair M. Jamen, Françoise Dubois, Thierry Chabaud, Sylvie Michiels, Stefan Treilleux, Isabelle Bourdon, Jean-Christophe Pérol, David Puisieux, Alain André, Fabrice Diaz, Jean-Jacques Marcel, Virginie Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer |
title | Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer |
title_full | Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer |
title_fullStr | Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer |
title_full_unstemmed | Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer |
title_short | Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer |
title_sort | low level of fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092774/ https://www.ncbi.nlm.nih.gov/pubmed/35545761 http://dx.doi.org/10.1186/s12885-022-09552-x |
work_keys_str_mv | AT nguyenvanlongflora lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT lardycleaudaudrey lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT carenedimitri lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT rossonicaroline lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT catezfrederic lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT rolletpaul lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT pionnathalie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT monchietdeborah lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT dolbeauagathe lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT martinmarjorie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT simionivalentin lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT braysusan lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT lebeherecdoris lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT moselefernanda lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT bouakkaibrahim lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT colombevermorelamelie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT odeyerlaetitia lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT diotalexandra lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT jordanleeb lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT thompsonalastairm lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT jamenfrancoise lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT duboisthierry lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT chabaudsylvie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT michielsstefan lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT treilleuxisabelle lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT bourdonjeanchristophe lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT peroldavid lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT puisieuxalain lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT andrefabrice lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT diazjeanjacques lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer AT marcelvirginie lowleveloffibrillarinaribosomebiogenesisfactorisanewindependentmarkerofpooroutcomeinbreastcancer |